Search

  • HOME
  • Search
Original Article
HLA‒B*58:01 and skin reactions in pediatric hematology and oncology patients treated with allopurinol
Parisa Maneechai, Cholada Ratanatharathron, Jassada Buaboonnam, Kleebsabai Sanpakit
Background: Allopurinol is widely used to prevent hyperuricemia in patients with tumor lysis syndrome. However, its use can trigger severe cutaneous adverse reactions (SCARs) with a mortality rate of approximately 11.39%. The human leukocyte antigen (HLA)–B*58:01 genotype is a major risk factor for SCARs. Although most studies to date have examined HLA–B*58:01 in Thai adults, data on pediatric patients are limited.
Purpose: Here we aimed to evaluate the...


TOPICS

Browse all articles >

ARTICLE CATEGORY

Browse all articles >

BROWSE ARTICLES
FOR CONTRIBUTORS
ABOUT
Editorial Office
Korean Pediatric Society
#1606 Seocho World Officetel, 19 Seoun-ro, Seocho-ku, Seoul 06732, Korea
Tel: +82-2-3473-7306    Fax: +82-2-3473-7307    E-mail: office@e-cep.org                

Clinical and Experimental Pediatrics is an open access journal. All articles are distributed under the terms of the Creative Commons Attribution NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/)

Copyright © 2025 by Korean Pediatric Society.      Developed in M2PI